• View patient site
  • Order
Oncimmune
  • Our Company
    • About Oncimmune
    • Board of Directors
    • Scientific Board
    • Regulation & Quality
    • Press Releases
    • Events & News
  • Products
    • Lung Cancer Blood Test
    • Liver Cancer Blood Test
  • Resources
    • Industry Publications
    • Oncimmune Resources
    • Videos
  • Investors
    • Corporate Governance
    • Regulatory Newsflow
    • Share Price and Tools
    • Shareholder Analysis
    • Analyst Coverage
    • Results, Reports & Presentations
    • Corporate Documents
    • Investor & Advisor Contacts
    • Aim Rule 26
  • Contact Us
  • Our Company
    • About Oncimmune
    • Board of Directors
    • Scientific Board
    • Regulation & Quality
    • Press Releases
    • Events & News
  • Products
    • Lung Cancer Blood Test
    • Liver Cancer Blood Test
  • Resources
    • Industry Publications
    • Oncimmune Resources
    • Videos
  • Investors
    • Corporate Governance
    • Regulatory Newsflow
    • Share Price and Tools
    • Shareholder Analysis
    • Analyst Coverage
    • Results, Reports & Presentations
    • Corporate Documents
    • Investor & Advisor Contacts
    • Aim Rule 26
  • Contact Us

Early Cancer Detection Insights

September 01, 2013

An Audit of the Clinical Performance of EarlyCDT®—Lung

Read More
November 01, 2012

Challenges in Biomarker Development

Read More
May 01, 2012

Improved Specificity of the EarlyCDT®—Lung Test Through Additional Autoantibody Assays

Read More
July 01, 2011

EarlyCDT®—Lung Test: Audit of the First 1000 Patients in Clinical Practice

Read More
October 01, 2010

EarlyCDT®—Lung: QC measures reveal high precision, accuracy and robustness of a clinical test to aid in early lung cancer detection for high-risk individuals

Read More
October 01, 2010

Reproducibility of autoantibody measurements in normal individuals using the EarlyCDT®—Lung test

Read More
July 03, 2010

Clinical Validation of an Autoantibody Test for Lung Cancer

Read More
February 17, 2010

Technical validation of an autoantibody test for lung cancer

Read More
oncimmune
brand

Oncimmune Holdings Plc
Clinical Sciences Building,
Nottingham City Hospital
Hucknall Road, Nottingham,
NG5 1PB, United Kingdom
+44 (0)115 82 31869

 

Registered in England and Wales number 09818395

Oncimmune (USA) LLC
8960 Commerce Drive,
Building #6,
De Soto,
KS 66018, USA
1 913 583 9000
1 888 583 9030

Terms & Conditions Privacy Policy Cookies
twitter facebook linkedin